Do analysts rate DSY or DRMA?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Big Tree Cloud 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Dermata Therapeutics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has better valuation and earnings, DSY or DRMA?

Dermata Therapeutics has lower revenue, but higher earnings than Big Tree Cloud. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Big Tree Cloud $2.56M 6.49 -$32.53M N/A N/A Dermata Therapeutics N/A N/A -$7.56M -$4.39 N/A

Is DSY or DRMA more profitable?

Big Tree Cloud's return on equity of 0.00% beat Dermata Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Big Tree Cloud N/A N/A N/A Dermata Therapeutics N/A -166.66% -130.13%

Do analysts recommend MTEX or DRMA?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Mannatech 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Dermata Therapeutics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Do analysts rate DRMA or NHTC?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Dermata Therapeutics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Natural Health Trends 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Do analysts prefer NAII or DRMA?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Natural Alternatives International 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Dermata Therapeutics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Do analysts recommend DRMA or SNYR?

Synergy CHC has a consensus target price of $6.25, suggesting a potential upside of 6,806.08%. Given Synergy CHC's stronger consensus rating and higher probable upside, analysts clearly believe Synergy CHC is more favorable than Dermata Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Dermata Therapeutics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Synergy CHC 1 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.25

Dermata Therapeutics (DRMA) Competitors

$1.16 0.00 (0.00%)

Closing price 09/18/2026 04:00 PM Eastern

Extended Trading

$1.15 -0.01 (-0.86%)

As of 09/18/2026 05:38 PM Eastern

Compare

DRMA vs. DSY, MTEX, NHTC, NAII, and SNYR

Should you buy Dermata Therapeutics stock or one of its competitors? Dermata Therapeutics's main competitors and comparable companies include Big Tree Cloud (DSY), Mannatech (MTEX), Natural Health Trends (NHTC), Natural Alternatives International (NAII), and Synergy CHC (SNYR). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "personal care products" industry.

How does Dermata Therapeutics compare to Big Tree Cloud?

Big Tree Cloud (NASDAQ:DSY) and Dermata Therapeutics (NASDAQ:DRMA) are both small-cap consumer staples companies, but which is the superior stock? We will compare the two businesses based on the strength of their valuation, institutional ownership, profitability, analyst recommendations, earnings, dividends, risk and media sentiment.

60.2% of Big Tree Cloud shares are held by institutional investors. Comparatively, 8.7% of Dermata Therapeutics shares are held by institutional investors. 34.1% of Big Tree Cloud shares are held by insiders. Comparatively, 21.9% of Dermata Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Big Tree Cloud's return on equity of 0.00% beat Dermata Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Big Tree Cloud	N/A	N/A	N/A
Dermata Therapeutics	N/A	-166.66%	-130.13%

In the previous week, Big Tree Cloud's average media sentiment score of 0.00 equaled Dermata Therapeutics'average media sentiment score.

Company	Overall Sentiment
Big Tree Cloud	Neutral
Dermata Therapeutics	Neutral

Dermata Therapeutics has lower revenue, but higher earnings than Big Tree Cloud.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Big Tree Cloud	$2.56M	6.49	-$32.53M	N/A	N/A
Dermata Therapeutics	N/A	N/A	-$7.56M	-$4.39	N/A

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Big Tree Cloud	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Dermata Therapeutics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Big Tree Cloud has a beta of 0.61, suggesting that its stock price is 39% less volatile than the broader market. Comparatively, Dermata Therapeutics has a beta of 0.69, suggesting that its stock price is 31% less volatile than the broader market.

Summary

Big Tree Cloud beats Dermata Therapeutics on 5 of the 7 factors compared between the two stocks.

How does Dermata Therapeutics compare to Mannatech?

Mannatech (NASDAQ:MTEX) and Dermata Therapeutics (NASDAQ:DRMA) are both small-cap consumer staples companies, but which is the better business? We will compare the two companies based on the strength of their media sentiment, profitability, analyst recommendations, dividends, earnings, risk, valuation and institutional ownership.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Mannatech	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Dermata Therapeutics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

In the previous week, Mannatech's average media sentiment score of 0.00 equaled Dermata Therapeutics'average media sentiment score.

Company	Overall Sentiment
Mannatech	Neutral
Dermata Therapeutics	Neutral

Dermata Therapeutics has a net margin of 0.00% compared to Mannatech's net margin of -6.90%. Dermata Therapeutics' return on equity of -166.66% beat Mannatech's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Mannatech	-6.90%	-2,383.34%	-24.43%
Dermata Therapeutics	N/A	-166.66%	-130.13%

13.0% of Mannatech shares are held by institutional investors. Comparatively, 8.7% of Dermata Therapeutics shares are held by institutional investors. 47.5% of Mannatech shares are held by insiders. Comparatively, 21.9% of Dermata Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Mannatech has a beta of 0.75, indicating that its share price is 25% less volatile than the broader market. Comparatively, Dermata Therapeutics has a beta of 0.69, indicating that its share price is 31% less volatile than the broader market.

Dermata Therapeutics has lower revenue, but higher earnings than Mannatech. Mannatech is trading at a lower price-to-earnings ratio than Dermata Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Mannatech	$108.04M	0.13	-$15.21M	-$3.91	N/A
Dermata Therapeutics	N/A	N/A	-$7.56M	-$4.39	N/A

Summary

Mannatech beats Dermata Therapeutics on 6 of the 10 factors compared between the two stocks.

How does Dermata Therapeutics compare to Natural Health Trends?

Dermata Therapeutics (NASDAQ:DRMA) and Natural Health Trends (NASDAQ:NHTC) are both small-cap consumer staples companies, but which is the superior investment? We will compare the two businesses based on the strength of their earnings, media sentiment, risk, dividends, profitability, analyst recommendations, institutional ownership and valuation.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Dermata Therapeutics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Natural Health Trends	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

8.7% of Dermata Therapeutics shares are owned by institutional investors. Comparatively, 10.1% of Natural Health Trends shares are owned by institutional investors. 21.9% of Dermata Therapeutics shares are owned by company insiders. Comparatively, 12.9% of Natural Health Trends shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

In the previous week, Dermata Therapeutics' average media sentiment score of 0.00 equaled Natural Health Trends'average media sentiment score.

Company	Overall Sentiment
Dermata Therapeutics	Neutral
Natural Health Trends	Neutral

Dermata Therapeutics has a beta of 0.69, indicating that its share price is 31% less volatile than the broader market. Comparatively, Natural Health Trends has a beta of 0.92, indicating that its share price is 8% less volatile than the broader market.

Natural Health Trends has higher revenue and earnings than Dermata Therapeutics. Natural Health Trends is trading at a lower price-to-earnings ratio than Dermata Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Dermata Therapeutics	N/A	N/A	-$7.56M	-$4.39	N/A
Natural Health Trends	$39.78M	0.30	-$880K	-$0.16	N/A

Dermata Therapeutics has a net margin of 0.00% compared to Natural Health Trends' net margin of -4.51%. Natural Health Trends' return on equity of -8.00% beat Dermata Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Dermata Therapeutics	N/A	-166.66%	-130.13%
Natural Health Trends	-4.51%	-8.00%	-4.58%

Summary

Natural Health Trends beats Dermata Therapeutics on 7 of the 10 factors compared between the two stocks.

How does Dermata Therapeutics compare to Natural Alternatives International?

Natural Alternatives International (NASDAQ:NAII) and Dermata Therapeutics (NASDAQ:DRMA) are both small-cap consumer staples companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, dividends, analyst recommendations, media sentiment, risk, profitability, valuation and earnings.

Dermata Therapeutics has a net margin of 0.00% compared to Natural Alternatives International's net margin of -10.13%. Natural Alternatives International's return on equity of -12.21% beat Dermata Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Natural Alternatives International	-10.13%	-12.21%	-5.30%
Dermata Therapeutics	N/A	-166.66%	-130.13%

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Natural Alternatives International	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Dermata Therapeutics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

32.4% of Natural Alternatives International shares are owned by institutional investors. Comparatively, 8.7% of Dermata Therapeutics shares are owned by institutional investors. 20.8% of Natural Alternatives International shares are owned by company insiders. Comparatively, 21.9% of Dermata Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Natural Alternatives International has a beta of 0.36, meaning that its stock price is 64% less volatile than the broader market. Comparatively, Dermata Therapeutics has a beta of 0.69, meaning that its stock price is 31% less volatile than the broader market.

Dermata Therapeutics has lower revenue, but higher earnings than Natural Alternatives International. Natural Alternatives International is trading at a lower price-to-earnings ratio than Dermata Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Natural Alternatives International	$129.86M	0.09	-$13.57M	-$2.39	N/A
Dermata Therapeutics	N/A	N/A	-$7.56M	-$4.39	N/A

In the previous week, Natural Alternatives International's average media sentiment score of 0.00 equaled Dermata Therapeutics'average media sentiment score.

Company	Overall Sentiment
Natural Alternatives International	Neutral
Dermata Therapeutics	Neutral

Summary

Natural Alternatives International and Dermata Therapeutics tied by winning 5 of the 10 factors compared between the two stocks.

How does Dermata Therapeutics compare to Synergy CHC?

Dermata Therapeutics (NASDAQ:DRMA) and Synergy CHC (NASDAQ:SNYR) are both small-cap consumer staples companies, but which is the superior stock? We will compare the two companies based on the strength of their valuation, dividends, profitability, earnings, risk, analyst recommendations, media sentiment and institutional ownership.

8.7% of Dermata Therapeutics shares are held by institutional investors. 21.9% of Dermata Therapeutics shares are held by insiders. Comparatively, 32.9% of Synergy CHC shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

In the previous week, Synergy CHC had 4 more articles in the media than Dermata Therapeutics. MarketBeat recorded 4 mentions for Synergy CHC and 0 mentions for Dermata Therapeutics. Synergy CHC's average media sentiment score of 0.46 beat Dermata Therapeutics' score of 0.00 indicating that Synergy CHC is being referred to more favorably in the news media.

Company	Overall Sentiment
Dermata Therapeutics	Neutral
Synergy CHC	Neutral

Dermata Therapeutics has a beta of 0.69, meaning that its share price is 31% less volatile than the broader market. Comparatively, Synergy CHC has a beta of -0.25, meaning that its share price is 125% less volatile than the broader market.

Dermata Therapeutics has higher earnings, but lower revenue than Synergy CHC. Dermata Therapeutics is trading at a lower price-to-earnings ratio than Synergy CHC, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Dermata Therapeutics	N/A	N/A	-$7.56M	-$4.39	N/A
Synergy CHC	$30.38M	0.04	-$12.34M	-$1.40	N/A

Dermata Therapeutics has a net margin of 0.00% compared to Synergy CHC's net margin of -60.02%. Synergy CHC's return on equity of 0.00% beat Dermata Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Dermata Therapeutics	N/A	-166.66%	-130.13%
Synergy CHC	-60.02%	N/A	-30.30%

Synergy CHC has a consensus target price of $6.25, suggesting a potential upside of 6,806.08%. Given Synergy CHC's stronger consensus rating and higher probable upside, analysts clearly believe Synergy CHC is more favorable than Dermata Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Dermata Therapeutics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Synergy CHC	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25

Summary

Synergy CHC beats Dermata Therapeutics on 11 of the 15 factors compared between the two stocks.

Get Dermata Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding DRMA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

DRMA vs. The Competition

Export

Metric	Dermata Therapeutics	Personal Care Products Industry	Consumer Staples Sector	NASDAQ Exchange
Market Cap	$4.67M	$22.84B	$15.55B	$13.19B
Dividend Yield	N/A	4.70%	3.25%	12.81%
P/E Ratio	-0.26	20.08	14.15	25.40
Price / Sales	N/A	12.68	262,948.99	89.45
Price / Cash	N/A	26.25	56.66	51.42
Price / Book	0.53	2.88	4.69	6.33
Net Income	-$7.56M	$1.13B	$836.60M	$358.33M
7 Day Performance	-2.52%	-2.39%	-0.95%	1.12%
1 Month Performance	-15.94%	-2.09%	-2.88%	-2.39%
1 Year Performance	-78.64%	-14.84%	10.46%	5.35%

Dermata Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
DRMA Dermata Therapeutics	0.5732 of 5 stars	$1.16 flat	N/A	-78.6%	$4.67M	N/A	N/A	9
DSY Big Tree Cloud	0.8458 of 5 stars	$3.48 -4.1%	N/A	-87.4%	$16.54M	$2.56M	N/A	82
MTEX Mannatech	0.3594 of 5 stars	$7.85 -4.2%	N/A	-14.9%	$15.15M	$108.04M	N/A	250	Gap Up
NHTC Natural Health Trends	0.545 of 5 stars	$1.51 +0.4%	N/A	-70.0%	$12.92M	$39.78M	N/A	140
NAII Natural Alternatives International	0.8922 of 5 stars	$1.99 +0.8%	N/A	-40.1%	$12.46M	$141.87M	N/A	290

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:DRMA) was last updated on 9/20/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Dermata Therapeutics (DRMA) Competitors

DRMA vs. DSY, MTEX, NHTC, NAII, and SNYR

How does Dermata Therapeutics compare to Big Tree Cloud?

Summary

How does Dermata Therapeutics compare to Mannatech?

Summary

How does Dermata Therapeutics compare to Natural Health Trends?

Summary

How does Dermata Therapeutics compare to Natural Alternatives International?

Summary

How does Dermata Therapeutics compare to Synergy CHC?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

DRMA vs. The Competition

Dermata Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Dermata Therapeutics (DRMA) Competitors

DRMA vs. DSY, MTEX, NHTC, NAII, and SNYR

How does Dermata Therapeutics compare to Big Tree Cloud?

Do insiders and institutionals have more ownership in DSY or DRMA?

Is DSY or DRMA more profitable?

Does the media favor DSY or DRMA?

Which has better valuation and earnings, DSY or DRMA?

Do analysts rate DSY or DRMA?

Which has more volatility and risk, DSY or DRMA?

Summary

How does Dermata Therapeutics compare to Mannatech?

Do analysts recommend MTEX or DRMA?

Does the media prefer MTEX or DRMA?

Is MTEX or DRMA more profitable?

Do insiders and institutionals hold more shares of MTEX or DRMA?

Which has more volatility & risk, MTEX or DRMA?

Which has better valuation & earnings, MTEX or DRMA?

Summary

How does Dermata Therapeutics compare to Natural Health Trends?

Do analysts rate DRMA or NHTC?

Do insiders & institutionals hold more shares of DRMA or NHTC?

Does the media refer more to DRMA or NHTC?

Which has more volatility & risk, DRMA or NHTC?

Which has higher earnings & valuation, DRMA or NHTC?

Is DRMA or NHTC more profitable?

Summary

How does Dermata Therapeutics compare to Natural Alternatives International?

Is NAII or DRMA more profitable?

Do analysts prefer NAII or DRMA?

Do institutionals & insiders have more ownership in NAII or DRMA?

Which has more risk and volatility, NAII or DRMA?

Which has higher earnings & valuation, NAII or DRMA?

Does the media prefer NAII or DRMA?

Summary

How does Dermata Therapeutics compare to Synergy CHC?

Do institutionals and insiders hold more shares of DRMA or SNYR?

Does the media refer more to DRMA or SNYR?

Which has more volatility & risk, DRMA or SNYR?

Which has preferable valuation and earnings, DRMA or SNYR?

Is DRMA or SNYR more profitable?

Do analysts recommend DRMA or SNYR?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

DRMA vs. The Competition

Dermata Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools